GlassScriptPhysician profile
Joseph P Phillips
NPI 1366550758
$8,900.56
in general payments reported to CMS, 2019-2025
34 companies · $1,331 in 2025
The $1,331 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $582 · 2021: $1,440 · 2022: $1,474 · 2023: $1,430 · 2024: $1,509 · 2025: $1,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,161 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,160.70 |
| Education | $109.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,408.71 | 2019-2025 | |
| Janssen Biotech, INC. | $862.00 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $654.98 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $554.34 | 2019-2023 | Xifaxan, Trulance |
| Pfizer INC. | $516.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $484.35 | 2019-2025 | Entyvio |
| Daiichi Sankyo INC. | $243.20 | 2019-2024 | Injectafer |
| Qol Medical, LLC | $231.28 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $220.05 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $197.95 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $164.54 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $162.75 | 2021-2024 | Dificid |
| Ardelyx, INC. | $141.22 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $137.55 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $107.34 | 2024-2025 | Vegzelma, Zymfentra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $95.99 | 2024-2025 | Zenpep |
| Amgen INC. | $86.20 | 2020-2023 | Avsola, Amjevita |
| Madrigal Pharmaceuticals | $85.19 | 2024-2025 | Resmetirom, Rezdiffra |
| Ethicon US, LLC | $68.51 | 2019 | |
| Braintree Laboratories, INC. | $58.34 | 2019-2024 | Suflave |
| Shire North American Group INC | $57.67 | 2019 | |
| Siemens Medical Solutions USA, INC. | $56.75 | 2024 | Magnetom Sola, Atellica Ch 930 Analyzer |
| Genzyme Corporation | $50.16 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $46.62 | 2021-2023 | Linzess |
| Redhill Biopharma INC. | $41.49 | 2020-2021 | |
| Novo Nordisk INC | $37.95 | 2021-2025 | Saxenda, Wegovy |
| Abbott Laboratories | $27.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $22.93 | 2023-2025 | Voquezna |
| Dynavax Technologies Corporation | $15.55 | 2019 | |
| Capsovision, INC. | $14.67 | 2025 | Capsocam Plus |
| Lilly USA, LLC | $14.13 | 2025 | Omvoh |
| Allergan, INC. | $11.28 | 2020 | |
| Echosens North America, INC. | $11.13 | 2019 | |
| Ucb, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.